Angioplasty and stenting for peripheral arterial disease of the lower limbs: an overview of Cochrane Reviews
References
Additional references
Antithrombotic Trialists' Collaboration. Collaborative meta‐analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324(7329):71‐86.
Beard JD. Chronic lower limb ischaemia. BMJ 2000;320:854. [DOI: https://doi.org/10.1136/bmj.320.7238.854]
Bekken J, Jongsma H, Ayez N, Hoogewerf CJ, Van Weel V, Fioole B. Angioplasty versus stenting for iliac artery lesions. Cochrane Database of Systematic Reviews 2015, Issue 5. [DOI: 10.1002/14651858.CD007561.pub2]
Bosch JL, Hunink MG. Meta‐analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology 1997;204(1):87‐96.
Bosch JL, van der Graaf Y, Hunink MG. Health‐related quality of life after angioplasty and stent placement in patients with iliac artery occlusive disease: results of a randomized controlled clinical trial. The Dutch Iliac Stent Trial Study Group. Circulation 1999;99(4):3155‐60.
CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348(9038):1329‐39.
Chowdhury MM, McLain AD, Twine CP. Angioplasty versus bare metal stenting for superficial femoral artery lesions. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD006767.pub3]
Chua B, Robless P, Stansby GP. Endoluminal stents for superficial femoral and popliteal artery occlusions in patients with lower limb peripheral artery disease. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006644]
Cikrit DF, Gustafson PA, Dalsing MC, Harris VJ, Lalka SG, Sawchuk AP. Long‐term follow‐up of the Palmaz stent for iliac occlusive disease. Surgery 1995;118(4):608‐14.
Diabetes Control and Complications Trial. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. American Journal of Cardiology 1995;75(14):894‐903.
Dormandy J, Rutherford RB. Management of peripheral arterial disease (PAD). TASC working group. TransAtlantic Inter‐Society Consensus (TASC). Journal of Vascular Surgery 2000;31(1 Part 2):S1‐296.
Fokkenrood HJP, Bendermacher BLW, Lauret GJ, Willigendael EM, Prins MH, Teijink JAW. Supervised exercise therapy versus non‐supervised exercise therapy for intermittent claudication. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD005263.pub3]
Fontaine R, Kim M, Kieny R. Die chirurgische Behandlung der peripheren Durch‐blutungsstörungen. Helvetica Chimita Acta 1954;21(5‐6):499‐533.
Fowkes FGR. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. International Journal of Epidemiology 1988;17(2):248‐54.
Fowkes FGR, Housley E, Cawood EHH, MacIntyre CCA, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. International Journal of Epidemiology 1991;20(2):384‐92.
Gray BH, Sullivan TM, Childs MB, Young JR, Olin JW. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long‐segment superficial femoral artery disease after suboptimal angioplasty. Journal of Vascular Surgery 1997;25(1):74‐83.
Hiatt WR. Pathophysiology of intermittent claudication in peripheral arterial disease. Cardiology Rounds2006; Vol. 10, issue 1.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hirsch AT, Treat‐Jacobson D, Lando HA, Hatsukami DK. The role of tobacco cessation, antiplatelet and lipid‐lowering therapies in the treatment of peripheral arterial disease. Vascular Medicine 1997;2(3):43‐51.
Hsu CCT, Rophael JA, Mofidi R, Kwan GNC, van Driel ML. Percutaneous transluminal arterial angioplasty versus stenting for infrapopliteal arterial lesions in critical limb ischaemia. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD009195]
Isner J, Rosenfield K. Redefining the treatment of peripheral artery disease: role of percutaneous revascularization. Circulation 1993;88(4 pt 1):1534‐57.
Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below‐the‐knee arteries: A supplement to the inter‐society consensus for the management of peripheral arterial disease (TASC II). Catheterization and Cardiovascular Interventions 2015;86(4):611‐25.
Katsanos K, Spiliopoulos S, Paraskevopoulos I, Diamantopoulos A, Karnabatidis D. Systematic review and meta‐analysis of randomized controlled trials of paclitaxel‐coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailability. Journal of Endovascular Therapy 2016;23(2):356‐70.
Kayssi A, Al‐Atassi T, Oreopoulos G, Roche‐Nagle G, Tan KT, Rajan DK. Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database of Systematic Reviews 2016, Issue 8. [DOI: 10.1002/14651858.CD011319.pub2]
Kayssi A, Al‐Jundi W, Papia G, Kucey DS, Forbes T, Rajan DK, et al. Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in‐stent restenosis of the femoropopliteal arteries. Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD012510]
Kügler CFA, Rudofsky G. The challenges of treating peripheral arterial disease. Vascular Medicine 2003;8(2):109‐14.
Laird JR, Schneider PA, Tepe G, Brodmann M, Zeller T, Metzger C, et al. IN.PACT SFA Trial Investigators. Durability of treatment effect using a drug‐coated balloon for femoropopliteal lesions: 24‐month results of IN.PACT SFA. Journal of the American College of Cardiology 2015;66(21):2329‐38.
Lane R, Ellis B, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD000990.pub3]
Lassila R, Lepantalo M. Cigarette smoking and the outcome after lower limb arterial surgery. Acta Chirurgica Scandinavica 1988;154(11‐12):635‐40.
Li Q, Zeng H, Liu F. High ankle‐brachial index indicates cardiovascular and peripheral arterial disease in patients with type 2 diabetes. Angiology 2015;66(10):918‐24. [DOI: 10.1177/0003319715573657]
Lofberg AM, Lorelius LE, Karacagil S, Westman B, Almgren B, Berqgvist D. The use of below‐knee percutaneous transluminal angioplasty in arterial occlusive disease causing chronic critical limb ischemia. Cardiovascular Interventional Radiology 1996;19(5):317‐22.
Lu L, Mackay DF, Pell JP. Meta‐analysis of the association between cigarette smoking and peripheral arterial disease. Heart 2014;100(5):414‐23. [DOI: 10.1136/heartjnl‐2013‐304082]
McDermott M, Greenland P, Liu K, Guralnik J, Criqui M, Dolan N, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001;286(13):1599‐606.
Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation 1997;96(1):44‐9.
National Institute for Health and Clinical Excellence. Lower limb peripheral arterial disease: diagnosis and management. NICE clinical guideline 147. guidance.nice.org.uk/cg147 (accessed 14 November 2013)August 2012.
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter‐Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Journal of Vascular Surgery 2007;45(1):S5‐67.
O'Keeffe ST, Woods BO, Beckmann CF. Percutaneous transluminal angioplasty of the peripheral arteries. Cardiology Clinics 1991;9(4):515‐22.
Ostchega Y, Paulose‐Ram R, Dillon CF. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999‐2004. Journal of the American Geriatrics Society 2007;55(4):583‐9.
Peach G, Griffin M, Jones KG, Thompson MM, Hinchcliffe RJ. Diagnosis and management of peripheral arterial disease. BMJ 2012;345:e5208.
Pfaffenbarger RS, Hyde RT, Wing AL, Lee IM, Jung DL, Kampert JB. The association of changes in physical activity level and other lifestyle characteristics among mortality with men. New England Journal of Medicine 1993;328(8):538‐45.
Price JF, Mowbray PI, Lee AJ, Rumley A, Lowe GD, Fowkes FGR. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. European Heart Journal 1999;20(5):344‐53.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rosenfield K, Jaff MR, White CJ, Rocha‐Singh K, Mena‐Hurtado C, Metzger DC, et al. LEVANT 2 Investigators. Trial of a paclitaxel‐coated balloon for femoropopliteal artery disease. New England Journal of Medicine 2015;373(2):145‐53.
Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. Journal of Vascular Surgery 1997;26(3):517‐38.
Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, et al. The LEVANT I (Lutonix paclitaxel‐coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first‐in‐human randomized trial of low‐dose drug‐coated balloon versus uncoated balloon angioplasty. JACC. Cardiovascular Interventions 2014;7(1):10‐9.
Scheinert D, Schulte KL, Zeller T, Lammer J, Tepe G. Paclitaxel‐releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve‐month results from the BIOLUX P‐I randomized trial. Journal of Endovascular Therapy 2015;22(1):14‐21.
Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999‐2000. Circulation 2004;110(6):738‐43.
Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta‐analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Annals of Internal Medicine 2004;141(6):421‐31.
Shea BJ, Grimshaw JM, Wells GA, Boers MB, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007;7:10.
Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of peripheral arterial disease. A national clinical guideline. 2006. www.sign.ac.uk/pdf/sign89.pdf (accessed 13 November 2013).
Smith I, Franks PJ, Greenhalgh RM, Poulter NR, Powell JT. The influence of smoking cessation and hyperglyceridaemia on the progression of peripheral arterial disease and the onset of critical limb ischemia. European Journal of Vascular and Endovascular Surgery 1996;11(4):402‐8.
Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. IN.PACT SFA Trial Investigators. Drug‐coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12‐month results from the IN.PACT SFA randomized trial. Circulation 2015;131(5):495‐502.
Tepe G, Schnorr B, Albrecht T, Brechtel K, Claussen CD, Scheller B, et al. Angioplasty of femoral‐popliteal arteries with drug‐coated balloons: 5‐year follow‐up of the THUNDER trial. JACC. Cardiovascular Interventions 2015;8(1 pt A):102‐8.
Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel‐coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 2008;118(16):1358‐65.
Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U, et al. Paclitaxel‐coated balloons reduce restenosis after femoro‐popliteal angioplasty: evidence from the randomized PACIFIER trial. Circulation. Cardiovascular Interventions 2012;5(6):831‐40.
White CJ, Gray WA. Endovascular therapies for peripheral arterial disease: An evidence‐based review. Circulation 2007;116(19):2203‐15.
Willigendael EM, Teijink JA, Bartelink ML, Kuiken BW, Boiten J, Moll FL, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. Journal of Vascular Surgery 2004;40(6):1158‐6.
Zeller T, Rastan A, Macharzina R, Tepe G, Kaspar M, Chavarria J, et al. Drug‐coated balloons vs. drug‐eluting stents for treatment of long femoropopliteal lesions. Journal of Endovascular Therapy 2014;21(3):359‐68.
